Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 5Thoracic 3Breast 3Other hematologic neoplasm 2Lymphoid 2Gynecologic 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1Other solid neoplasm 1Myeloid 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Lung Neoplasms 2Triple Negative Breast Neoplasms 1Pleural Effusion, Malignant 1Ovarian Neoplasms 1Mesothelioma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Carboplatin 463Cisplatin 379Paclitaxel 313Pemetrexed 300Docetaxel 242Erlotinib Hydrochloride 240Gemcitabine 232pembrolizumab 173Radiotherapy 172Bevacizumab 169Nivolumab 130Etoposide 106Gefitinib 95Vinorelbine 84durvalumab 71atezolizumab 68Cetuximab 65Topotecan 61Drug Therapy 57Ipilimumab 55Irinotecan 54osimertinib 53Radiosurgery 52Afatinib 51Surveys and Questionnaires 38130-nm albumin-bound paclitaxel 38Albumin-Bound Paclitaxel 37Taxes 35Cyclophosphamide 35Surgical Procedures, Operative 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Valacyclovir × Thoracic × Clear all
NCT03131037 2025-07-11

Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer

Candel Therapeutics, Inc.

Phase 1 Completed
12 enrolled
Thoracic

Lung Neoplasms

NCT03004183 2024-10-15

STOMP

The Methodist Hospital Research Institute

Phase 2 Completed
57 enrolled 12 charts
BreastThoracic

Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms

NCT01997190 2023-08-25

MpeTK01

Candel Therapeutics, Inc.

Phase 1 Completed
19 enrolled
BreastGynecologicOther solid neoplasmThoracic

Breast Neoplasms, Lung Neoplasms, Mesothelioma, Ovarian Neoplasms, Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡